Health care resource utilisation in primary care prior to and after a diagnosis of Alzheimer’s disease: a retrospective, matched case–control study in the United Kingdom

BMC Geriatrics

Alan Lenox-Smith³  Allen Nyhuis¹  Michael Happich¹  Catherine Reed²  Lei Chen¹ 

[1] Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285, USA;Lilly UK, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK;Lilly UK, Lilly House, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK

关键词: Primary care;    United Kingdom;    Dementia;    Alzheimer’s disease;   

Others  :  848387
DOI  :  10.1186/1471-2318-14-76

 received in 2014-01-08, accepted in 2014-06-11,  发布年份 2014

【 摘 要 】

Background

This study examined medical resource utilisation patterns in the United Kingdom (UK) prior to and following Alzheimer’s disease (AD) diagnosis.

Methods

A patient cohort aged 65 years and older with newly diagnosed AD between January 2008 and December 2010 was identified through the UK’s Clinical Practice Research Datalink (CPRD). Patients with a continuous record in the CPRD (formerly the General Practice Research Database [GPRD]) for both the 3 years prior to, and the 1 year following, AD diagnosis were eligible for inclusion. A control cohort was identified by matching general older adult (GOA) patients to patients with AD based on year of birth, gender, region, and Charlson Comorbidity Index at a ratio of 2:1. Medical resource utilisation was calculated in 6-month intervals over the 4-year study period. Comparisons between AD and GOA control cohorts were conducted using conditional logistic regression for patient characteristics and a generalised linear model for resource utilisation.

Results

Data for the AD cohort (N = 3,896) and matched GOA control cohort (N = 7,792) were extracted from the CPRD. The groups were 65% female and the AD cohort had a mean age of 79.9 years (standard deviation 6.5 years) at the date of diagnosis. Over the entire study period, the AD cohort had a significantly higher mean primary care consultation rate than the GOA cohort (p < .0001). While the GOA cohort primary care consultation rate gradually increased over the 4-year period (ranging from 5 to 7 consultations per 6-month period), increases were more pronounced in the AD cohort (ranging from 6 to 11 consultations per 6-month period, peaking during the 6-month periods immediately prior to and post diagnosis). The AD cohort also had a higher overall specialty referral rate than the GOA cohort over the 4-year period (37% vs. 25%, respectively; p < .0001); the largest difference was during the 6 months immediately prior to AD diagnosis (17% vs. 5%, respectively; p < .0001).

Conclusions

In the UK, AD diagnosis is associated with significant increases in primary and secondary care resource utilisation, continuing beyond diagnosis. This evidence may be important to health care commissioners to facilitate effective mobilisation of appropriate AD-related health care resources.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B, on behalf of the CDBE2010 study group and the European Brain Council: The economic cost of brain disorders in Europe. Eur J Neurol 2012, 19:156-162.
• [2]Alzheimer’s Society: Dementia UK: The Full Report. London; 2007.
• [3]Paykel ES, Brayne C, Huppert FA, Gill C, Barkley C, Gehlhaar E, Beardsall L, Girling DM, Pollitt P, O’Connor D: Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry 1994, 51:325-332.
• [4]Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sterm Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
• [5]American Psychiatric Association: Mild Neurocognitive Disorder. Arlington, VA; 2013.
• [6]Gibson AK, Anderson KA: Difficult diagnoses: Family caregivers’ experiences during and following the diagnostic process for dementia. Am J Alzheimers Dis Other Demen 2011, 26:212-217.
• [7]Alzheimer’s Society: Dementia 2012: A National Challenge. London; 2012.
• [8]National Institute for Health and Clinical Excellence: Dementia: Supporting People with Dementia and Their Carers in Health and Social Care (NICE Clinical Guideline 42). London; 2012.
• [9]Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, König HH: Cost-of-illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psychiatr Scand 2010, 121:243-259.
• [10]Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, Fuchs A, Luppa M, Maier W, Mösch E, Pentzek M, Rieder-Heller SG, Tebarth F, Werle J, Weyerer S, Wiese B, Zimmermann T, König HH, AgeCoDe Study Group: Net costs of dementia by disease stage. Acta Psychiatr Scand 2011, 124:384-395.
• [11]Kronborg Andersen C, Søgaard J, Hansen E, Kragh-Sørensen A, Hastrup L, Andersen J, Andersen K, Lolk A, Nielsen H, Kragh-Sørensen P: The cost of dementia in Denmark: the Odense study. Dement Geriatr Cogn Disord 1999, 10:295-304.
• [12]The Prime Minister’s Challenge on Dementia: Delivering Major Improvements in Dementia Care and Research by 2015: A Report on Progress. London; 2012.
• [13]Albert SM, Glied S, Andrews H, Stern Y, Mayeux R: Primary care expenditures before the onset of Alzheimer’s disease. Neurology 2002, 59:573-578.
• [14]Ramakers IHGB, Visser PJ, Aalten P, Boesten JHM, Metsemakers JFM, Jolles J, Verhey FRJ: Symptoms of preclinical dementia in general practice up to five years before dementia diagnosis. Dement Geriatr Cogn Disord 2007, 24:300-306.
• [15]Eisele M, van den Bussche H, Koller D, Wiese B, Kaduszkiewicz H, Maier W, Glaeske G, Steinmann S, Wegscheider K, Schön G: Utilization patterns of ambulatory medical care before and after the diagnosis of dementia in Germany—results of a case-control study. Dement Geriatr Cogn Disord 2010, 29:475-483.
• [16]Leibson C, Owens T, O’Brien P, Pasquier Waring S, Tangalos E, Hanson V, Plevak M, Kokmen E: Use of physician and acute care services by persons with and without Alzheimer’s disease: a population a population-based comparison. J Am Geriatr Soc 1999, 47:864-869.
• [17]Helmer C, Pérès K, Pariente A, Pasquier F, Auriacombe S, Poncet M, Portet F, Rouaud O, Ritchie K, Tzourio C, Dartigues JF: Primary and secondary care consultations in elderly demented individuals in France. Results from the Three-City Study. Dement Geriatr Cogn Disord 2008, 26:407-415.
• [18]Jick H, Jick SS, Derby LE: Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1999, 302:766-768.
• [19]Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, Schlienger RG, Black C, Jick H: Validity of the General Practice Research Database. Epidemiology 2003, 14:630-632.
• [20]Clinical Practice Research Datalink. [http://www.cprd.com webcite]
• [21]Hospital Episode Statistics. [http://www.hscic.gov.uk/hes webcite]
• [22]Khan NF, Perera R, Harper S, Rose PW: Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010, 11:1.
• [23]Rowlands S, Moser K: Consultation rates from the general practice research database. Br J Gen Pract 2002, 52:658-660.
• [24]Wimo A, Reed CC, Dodel R, Belger M, Jones RW, Happich M, Argimon JM, Bruno G, Novick D, Vellas B, Haro JM: The GERAS study: a prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three European countries – study design and baseline findings. J Alzheimers Dis 2013, 36:385-399.
• [25]Hippisley-Cox J, Fenty J, Heaps M: Trends in Consultation Rates in General Practice 1995 to 2006: Analysis of the QRESEARCH Database. Final Report to the Information Centre and Department of Health. 2007.
• [26]Sigström R, Skoog I, Sacuiu S, Karlsson B, Klenfeldt IF, Waern M, Gustafson D, Östling S: The prevalence of psychotic symptoms and paranoid ideation in non-demented population samples aged 70–82 years. Int J Geriatr Psychiatry 2009, 24:1413-1419.
• [27]Östling S, Bäckman K, Waern M, Marlow T, Braam AW, Fichter M, Lawlor BA, Lobos A, Reischies FM, Copeland JRM, Skoog I: Paranoid symptoms and hallucinations among the older people in Western Europe. Int J Geriatr Psychiatry 2013, 28:573-579.
• [28]Forrest CB, Majeed A, Weiner JP, Carroll K, Bindman AB: Comparison of specialty referral rates in the United Kingdom and the United States: retrospective cohort analysis. BMJ 2002, 325:370-371.
• [29]Kirson NY, Hunter CA, Desai U, Cummings AKG, San Roman AM, Faries DE, Hardwick C, Birnbaum HG: Excess Costs Associated with Misdiagnosis of Alzheimer’s Disease among US Medicare Beneficiaries with Vascular Dementia or Parkinson’s Disease. Boston, MA, USA: Alzheimer’s Association International Conference; 2013. July 17 2013
• [30]Getsios D, Blume S, Ishuk K, Maclaine G, Hernandez L: An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement 2012, 8:22-30.